@article {MARUYAMA4345, author = {RYO MARUYAMA and SEIICHI SAITO and VLADIMIR BILIM and NOBORU HARA and TOSHIYUKI ITOI and KAZUTOSHI YAMANA and TSUTOMU NISHIYAMA and YOICHI ARAI and KOTA TAKAHASHI and YOSHIHIKO TOMITA}, title = {High Incidence of GalNAc Disialosyl Lactotetraosylceramide in Metastatic Renal Cell Carcinoma}, volume = {27}, number = {6C}, pages = {4345--4350}, year = {2007}, publisher = {International Institute of Anticancer Research}, abstract = {Background: In renal cell carcinoma (RCC), glycosphingolipids monosialosyl globopentaosylceramide (MSGb5) and GalNAc disialosyl lactotetraosylceramide (GalNAcDSLc4) were shown to be predictors of metastasis. Here we extended the research using a larger cohort of patients with a longer follow-up period, and reevaluate their relationship to malignant potential, metastasis and prognosis in patients with RCC. Patients and Methods: MSGb5 and GalNAcDSLc4 were examined in 114 primary RCCs by immunohistochemical method on cryostat sections. Results: GalNAcDSLc4 was detected in 13.2\% of RCCs and was associated with a significantly higher incidence of metastasis at the time of primary visit (60.0\% vs. 31.3\%, p=0.0419) as well as de novo metastasis during follow-up (33.3\% vs. 14.7\%), and a shorter survival (p=0.0399). MSGb5 was detected in 51.8\% of tumors and was not related to clinocopathological characteristics or survival. Conclusion: RCC patients with tumors positive for GalNAcDSLc4 are at higher risk of metastasis at the time of diagnosis and during follow-up. Copyright{\textcopyright} 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/27/6C/4345}, eprint = {https://ar.iiarjournals.org/content/27/6C/4345.full.pdf}, journal = {Anticancer Research} }